Mumbai-based pharma manufacturer FDC has received an approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Ciprofloxacin Ophthalmic Solution.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for ocular surface infections.</P>
</p><p class='TableClas'>The Company had recently received approval for Timolol Maleate Ophthalmic Solution. Another ANDA ofloxacin ophthalmic solution is in the final stages of approval.</P>
</p><p class='TableClas'></p></table>


FDC gets approval for Ciprofloxacin solution

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News